Announcement
30 Sep 2025
In September 2025, the United States government announced an agreement with Pfizer to implement most-favored-nation drug pricing for American patients. The agreement secured a three-year reprieve for Pfizer from prospective tariffs on the pharmaceutical industry.
Source
Sign in to access
Number of interventions
4
0 certainly harmful
4 likely harmful
0 liberalising
List of interventions
Implementation date
No implementation date
Revocation date:
No revocation date
Updated: 04 Nov 2025
FDI: Financial incentive
Recent update from 04 Nov 2025:
On 30 September 2025, the U.S. Administration announced an agreement with Pfizer Inc. Under the agreement, Pfizer committed to further its investments in manufacturing in the United States. In retu...
Sign in to see more
Updated: 13 Oct 2025
Localisation, nes
Recent update from 13 Oct 2025:
On 30 September 2025, the U.S. Administration announced an agreement with Pfizer Inc. Under the agreement, Pfizer will be exempt from future Section 232 tariffs on pharmaceutical products for three...
Sign in to see more
Updated: 13 Oct 2025
Tax or social insurance relief
Recent update from 13 Oct 2025:
On 30 September 2025, the U.S. Administration announced reaching an agreement with Pfizer Inc. Under the agreement, Pfizer will be exempt from future Section 232 tariffs on pharmaceutical products ...
Sign in to see more
Updated: 13 Oct 2025
Import tariff
Recent update from 13 Oct 2025:
On 30 September 2025, the U.S. Administration announced an agreement with Pfizer Inc, granting the company a three-year grace period from Section 232 pharmaceutical tariffs. In exchange for this ex...
Sign in to see more
Threads
See all
This state act is not part of any Thread yet.